Pfizer (PFE) Stock After Hours on December 9, 2025: Obesity Pill Deal, RSV Questions, and What to Watch Before the Opening Bell

Pfizer Inc. (NYSE: PFE) finished a volatile Tuesday session on December 9, 2025 under pressure, then stabilized in after-hours trading as investors digested a big new obesity-drug licensing deal and fresh headlines around RSV therapies. With the next U.S. market session opening on December 10, 2025, traders in Pfizer stock are lining up the key catalysts that could drive PFE’s next move.

How Pfizer Stock Traded on December 9, 2025

During regular trading on December 9, Pfizer shares slipped again:

Regular-session close: $25.33, down about 1.7% on the day ^[1]
Intraday range: roughly $25.13 to $26.13, with volume around 43–44 million shares, below the recent average session volume north of 50 million ^[2]

The weakness continues a choppy pattern for Pfizer stock in late 2025, with shares trading closer to the bottom half of their 52-week range of about $20.92 to $27.69. ^[3]

After-hours action “after the bell” on Dec. 9

Once the closing bell rang, PFE saw a mild bounce:

After-hours price: around $25.40, up roughly 0.3% from the regular close by late evening U.S. time ^[4]

So the headline for price action is: regular session weak, after-hours slightly firmer, as the market tried to price in a major new obesity-drug partnership.

Big Catalyst: Pfizer’s New YaoPharma Obesity Pill Deal

The main story behind Pfizer stock on December 9 is strategic, not just technical.

Pfizer announced an exclusive global collaboration and license agreement with YaoPharma, a subsidiary of China’s Shanghai Fosun Pharmaceutical, for YP05002, an early-stage oral GLP-1 receptor agonist being developed for chronic weight management. ^[5]

Key points of the deal:

Upfront payment: about $150 million to YaoPharma
Potential milestones: up to $1.9–2.1 billion tied to development, regulatory, and commercial achievements
Royalties: tiered royalties on future global sales if the drug is approved
Development stage: currently in Phase 1 clinical development for weight management

Strategically, this is Pfizer’s latest attempt to secure a meaningful position in the obesity and cardiometabolic drug market, a sector dominated today by injectable GLP-1 drugs like semaglutide and tirzepatide from rivals.

Importantly, Pfizer has twice stumbled in this field:

It discontinued lotiglipron in 2023 due to liver safety concerns.
In 2025, the company dropped a twice-daily version of danuglipron, another oral GLP-1 candidate, also linked to safety and tolerability issues. ^[6]

The YaoPharma partnership is therefore being read as:

A reset of Pfizer’s obesity strategy toward an externally sourced oral GLP-1 asset.
A signal that Pfizer is unwilling to abandon the multi-billion-dollar obesity opportunity, even after high-profile setbacks.

For Pfizer stock, this matters because obesity and cardiometabolic drugs are one of the potential growth pillars meant to offset post-COVID revenue declines and the looming patent cliff for older blockbusters.

Fundamental Backdrop: Cost Cuts, Guidance and Dividend Yield

The YaoPharma news lands on top of a broader restructuring and refocusing effort at Pfizer.

Cost-cutting and 2025 profit outlook

Earlier in 2025, Pfizer reported better-than-expected earnings as a large cost-cutting program began to bite. The company has:

Beat quarterly profit estimates, helped by restructuring and operational efficiencies. ^[7]
Raised its 2025 profit forecast, guiding full-year EPS to roughly $3.00–$3.15, above prior estimates and slightly ahead of many analyst expectations. ^[8]

That guidance, if achieved, makes the current share price in the mid-$20s look modestly valued on a price-to-earnings basis, particularly relative to peers with high GLP-1 exposure that trade at richer multiples.

High dividend as a cushion

At recent prices around $25–26, Pfizer’s annual dividend yield sits around 6.6–6.7%, unusually high for a mega-cap pharma stock. ^[9]

That yield:

Attracts income-focused investors, who see PFE as a bond-like equity with potential upside if the pipeline delivers.
Also signals market skepticism: a yield that high often means investors are pricing in significant risk to future earnings and cash flows.

What Wall Street is Saying About PFE Right Now

Despite the stock’s underwhelming performance, the consensus view is not outright bearish.

Valuation and “mispricing” debate

Several recent pieces argue Pfizer stock may be undervalued:

A recent analysis highlighted that at a price near $25.30–$25.40, Pfizer trades below estimates of its intrinsic value, pointing to cost cuts, pipeline assets, and non-COVID franchises as under-appreciated drivers. ^[10]
Another detailed review of Pfizer stock emphasized the 6.6% dividend yield and a complex macro and competitive backdrop, but still framed the shares as potentially attractive for long-term investors willing to tolerate near-term volatility. ^[11]

Recent forecasts from outlets tracking PFE project average 12-month price targets around the high-$20s (roughly $28–29), implying mid-teens percentage upside from current levels, with a wide range of views between the most bullish and most cautious analysts. ^[12]

Ratings and pipeline optimism

Overall, analyst ratings skew toward “Hold” with a tilt toward “Buy”, not a consensus “Sell.” ^[13]
Some recent research emphasizes that Pfizer still claims one of the largest drug pipelines in the industry, arguing that the market is overly focused on COVID declines and patent expiries and under-pricing long-term pipeline value. ^[14]
Independent forecasts in December 2025 have highlighted modest near-term performance but a possible rebound through 2030 if new products, including obesity and RSV franchises, scale as planned. ^[15]

In short, sentiment is cautiously constructive: plenty of skepticism, but also a clear contingent of investors and analysts who see a mispriced turnaround story rather than a melting ice cube.

RSV and Regulatory Noise: A Risk to Watch

Parallel to the obesity-drug story, investors in Pfizer stock are also watching RSV (respiratory syncytial virus) headlines.

Pfizer’s Abrysvo RSV vaccine has secured approvals in multiple regions, including in adults at increased risk in the EU and globally, and maternal immunization has been recommended by WHO. ^[16]
On December 9, regulatory news outlets highlighted that the U.S. FDA is reviewing the safety of infant RSV therapies, a category that includes monoclonal antibodies and interacts with the same disease space Pfizer is targeting. ^[17]

While this review does not automatically imply negative outcomes for Pfizer, any change in RSV clinical or regulatory guidance could affect:

The commercial trajectory of Abrysvo and related RSV products.
Investor perception of vaccine-related revenue streams in Pfizer’s long-term model.

For Pfizer stock traders heading into December 10, RSV safety headlines are a potential swing factor that could add volatility if new details emerge.

What to Watch Before the Stock Market Opens on December 10, 2025

Putting it all together, here’s what matters most for Pfizer shareholders and traders before the bell on December 10:

1. Market reaction to the YaoPharma obesity pill deal

The key question: Does the market treat this as a serious new growth driver or just another GLP-1 experiment?

Things to watch:

Early commentary from analysts and strategists on the deal’s economics (upfront vs. milestones, royalty structure, and the cost of catching up in obesity). ^[18]
Discussion around clinical risk: Phase 1 oral GLP-1 programs can fail on efficacy, tolerability, or safety—especially given Pfizer’s history in this class.
Comparisons to Eli Lilly and Novo Nordisk, where obesity revenue and expectations are already embedded in lofty valuations.

2. Pre-market and early-session trading dynamics

Even without an earnings report, Pfizer can move sharply on news flow, options positioning, and macro sentiment.

Heading into the new session, watch for:

Pre-market price action and volume relative to normal levels—are traders leaning bullish on the obesity deal, or fading the news? (As of the latest data, after-hours pricing was only modestly higher than the close, suggesting no explosive reaction yet.) ^[19]
Whether PFE can hold support around the mid-$25s or revisits the lower part of its 52-week range near $21 if sentiment sours. ^[20]

3. Macro backdrop: Fed, rates and risk appetite

The broader U.S. market is currently trading in a holding pattern as investors watch the Federal Reserve’s December policy meeting and potential 2026 rate-cut signals. ^[21]

For Pfizer stock, that matters because:

Higher for longer rates keep pressure on high-dividend and defensive names by making bond yields more competitive.
A risk-on rally tends to favor growth and AI/tech over defensives, while a risk-off move can push flows back into large pharma and healthcare.

4. Ongoing narrative: Turnaround value play or value trap?

Going into December 10, the market’s story about Pfizer stock is caught between two competing narratives:

Turnaround value play:
- Cost cuts working
- Pipeline broad (oncology, RSV, vaccines, now another obesity shot on goal)
- Dividend yield over 6% while the stock trades near the low end of its multi-year range
Value trap concern:
- COVID revenues shrinking faster than new products ramp
- Patent cliffs on older blockbusters
- High competition in obesity, oncology, and vaccines from better-positioned rivals

Short-term trading on December 10 will likely be about which narrative traders emphasize when they see overnight headlines and early price action.

Bottom Line: Key Takeaways on Pfizer (PFE) Before the December 10 Open

Price context: PFE closed December 9, 2025 at $25.33, down about 1.7%, then stabilized slightly higher in after-hours trading around $25.40. ^[22]
Major catalyst: A multi-billion-dollar obesity-drug licensing deal with YaoPharma gives Pfizer another shot at the oral GLP-1 market after previous failures—strategically important but still early-stage and risky. ^[23]
Fundamentals: Cost-cutting and improved 2025 guidance support earnings, and a ~6.6% dividend yield offers income, but the market remains skeptical about long-term growth and patent-cliff exposure. ^[24]
Risks: Regulatory scrutiny around RSV therapies and broader competitive pressure in vaccines and obesity drugs are meaningful overhangs. ^[25]
Sentiment: Analyst views cluster around Hold to cautious Buy, with several recent pieces arguing that Pfizer stock is mispriced to the downside relative to its pipeline and cash flow potential. ^[26]

For investors and traders looking at Pfizer before the U.S. market opens on December 10, 2025, the story is less about a single number and more about how the obesity deal, RSV newsflow, and macro backdrop all interact with a high-yield, low-expectations pharma giant.